Company intelligence / Profile preview

RingConn

Delaware, United States

Ownership: Private
Employees: ~51
Development stage: Other

Overview

RingConn's Gen 2 Smart Ring is commercially launched and offers real-time monitoring of sleep (including sleep apnea with 90.7% accuracy), stress, activity, and women's health, with over 200,000 users worldwide. The system is being evaluated for additional medical features and is pending FDA clearance for sleep apnea screening.

Therapeutic areas: NeurologyPsychiatryPulmonologyOtherWomen's Health
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Partnerships

Target

Beyond the preview

Go deeper on RingConn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RingConn.

Explore the full profile